795,716 Shares in OPKO Health, Inc. $OPK Bought by Bank of America Corp DE

Key Points

• Bank of America acquired 795,716 OPKO Health shares during the second quarter, worth approximately $1.19 million and representing about 0.11% of the company. Institutional investors collectively own 64.63% of OPKO.
• Analyst sentiment is mixed, with ratings ranging from Strong Buy to Sell; MarketBeat reports a consensus rating of Hold and a target price of $1.55.
• OPKO exceeded quarterly expectations, reporting an adjusted loss of $0.01 per share versus the $0.08 consensus loss and revenue of $163.58 million, up 4.3% year over year.

Bank of America Corp DE acquired a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 795,716 shares of the biotechnology company's stock, valued at approximately $1,194,000. Bank of America Corp DE owned about 0.11% of OPKO Health at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in OPKO Health during the second quarter valued at approximately $55,468,000. AWM Investment Company Inc. bought a new position in OPKO Health during the second quarter worth $3,165,000. Bank of New York Mellon Corp bought a new position in OPKO Health during the second quarter worth $1,995,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in OPKO Health in the second quarter worth $618,000. Finally, Legal & General Group Plc acquired a new position in OPKO Health in the second quarter worth $520,000. Institutional investors own 64.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on OPK. Weiss Ratings reissued a "sell (d-)" rating on shares of OPKO Health in a report on Thursday, August 13th. Wall Street Zen upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th. Zacks Research raised shares of OPKO Health from a "hold" rating to a "strong-buy" rating in a report on Monday. Finally, HC Wainwright restated a "buy" rating on shares of OPKO Health in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, OPKO Health has a consensus rating of "Hold" and a consensus target price of $1.55.

OPKO Health Stock Performance

OPK opened at $1.57 on Friday. The business's 50 day moving average is $1.50 and its 200-day moving average is $1.35. The stock has a market cap of $1.17 billion, a PE ratio of -17.44 and a beta of 1.51. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. OPKO Health, Inc. has a twelve month low of $0.98 and a twelve month high of $1.75.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The firm had revenue of $163.58 million for the quarter, compared to the consensus estimate of $131.23 million. During the same quarter in the previous year, the business earned ($0.19) EPS. The firm's revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts predict that OPKO Health, Inc. will post -0.23 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Its diagnostics business includes BioReference Laboratories, which provides clinical laboratory testing and specialty diagnostic services in the United States, and the 4Kscore test, a blood-based test designed to help assess the risk of aggressive prostate cancer.

OPKO's pharmaceutical activities include products and development programs in areas such as endocrinology, nephrology, and other specialty-care markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.